Organisational change
Ringvold joined Navamedic in 2004 and has held a strategic role in the development of the company and the listing of its shares on Oslo Børs at the end of March this year.
-We are grateful for Ringvold's contributions in an important period for Navamedic, and wish him all the best in his new job, says CEO Øyvind W. Brekke in Navamedic ASA.
For further information, please contact:
Øyvind W. Brekke, CEO
E-mail: oyvind.brekke@navamedic.com
Office: +47 67 11 25 40
Mobile: +47 91 19 81 64
About Navamedic ASA:
Navamedic is a Norwegian speciality pharmaceutical company focusing on the development and production of glucosamine HCl (hydrochloride) based medicines. Glucosamine is a generic active ingredient which relieves pain and improves function in patients with mild to moderate osteoarthritis. The product has a favourable safety profile. Osteoarthritis is a chronic disease which affects a large and growing share of the world`s population. Navamedic aims to become a leading company in the glucosamine industry, with a competitive advantage in proprietary production technology. The company`s products will be sold through a network of sales, marketing and distribution partners. Navamedic`s product Glucomed has been approved as a medicine against osteoarthritis in 20 European countries. The product was launched in Sweden in December 2005, and Navamedic prepares product launches in further European countries in 2006.